Covid Related Vaccine Companies

People have been very excited to jump into Covid related Vaccine companies, but I remain skeptical. Let’s take a look at some of the deals these companies have received. Some of these companies have already received funds to aid in the development of the vaccines, but the language in the details is what concerns me. With the Moderna, the government reached a deal for 100 million doses and the federal government has the option to purchase up to 400 million additional doses. This is worth up to $1.53 billion. With Johnson & Johnson a deal was reached again for 100 million doses and gives the federal government the option to order an additional 200 million doses. Sanofi & GlaxoSmithKline again the HHS announced it would pay to help develop and deliver 100 million doses and the U.S. will have the option to order an additional 500 million doses. Pfizer and BioNTech, the US agreed to buy 100 million doses and the agreement allows the U.S. to acquire an additional 500 million vaccine doses. Novavax, the company will provide 100 million doses as part of a deal with the US government. AstraZeneca, the U.S. will receive at least 300 million doses as part of its investment. The problem here is there are several companies racing to develop this vaccine and as you can see there may be deals with multiple companies if the vaccines prove to be successful. If multiple do produce the vaccine this would mean less revenue for the successful companies as it would be split among more players. Also, if one proves to be more effective the stocks of the other companies would likely plummet.